At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 439 enrolled
Drug / intervention
Roflumilast 0.3% cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects With Chronic Plaque Psoriasis
In Brief
A Phase 3 clinical trial evaluating Roflumilast 0.3% cream and Vehicle Cream for Chronic Plaque Psoriasis. Completed, enrolled 439 participants across 40 sites in 2 countries.
Detailed Summary
This is a double-blind, parallel group, vehicle-controlled study to assess the safety and efficacy of roflumilast (ARQ-151) 0.3% cream vs vehicle (placebo) cream for treatment of chronic plaque psoriasis (CPP) in adult participants with 2 to 20% body surface area (BSA) of CPP.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Plaque Psoriasis
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedDec 2019
Primary CompletionNov 2020
TodayJul 2026
First PostedDec 26, 2019
Enrollment StartDec 20, 2019
Primary CompletionNov 16, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 6.5 years ago
Interventions
Roflumilast 0.3% creamdrug
Roflumilast 0.3% cream for topical application.
Vehicle Creamdrug
Vehicle cream for topical application.